Last reviewed · How we verify
SH D 593 B (Miranova)
SH D 593 B is a selective progesterone receptor modulator that modulates progesterone signaling to treat gynecological and reproductive disorders.
SH D 593 B is a selective progesterone receptor modulator that modulates progesterone signaling to treat gynecological and reproductive disorders. Used for Uterine fibroids (leiomyomas), Endometriosis.
At a glance
| Generic name | SH D 593 B (Miranova) |
|---|---|
| Sponsor | Bayer |
| Drug class | Selective progesterone receptor modulator (SPRM) |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Reproductive Health |
| Phase | Phase 3 |
Mechanism of action
As a selective progesterone receptor modulator (SPRM), SH D 593 B binds to progesterone receptors with tissue-selective activity, allowing both agonist and antagonist effects depending on the tissue context. This mechanism enables it to modulate endometrial proliferation and uterine contractility while potentially preserving ovarian function, making it suitable for conditions like uterine fibroids and endometriosis.
Approved indications
- Uterine fibroids (leiomyomas)
- Endometriosis
Common side effects
- Hot flashes
- Headache
- Amenorrhea
- Vaginal bleeding changes
Key clinical trials
- Comparative Cycle Control Europe (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |